Search
Neocartilage
go.drugbank.com/drugs/DB05257InvestigationalNeocartilage is the only scaffold-free living cartilage graft on the market. … Neocartilage, a novel cartilage regeneration treatment. Neocartilage is generated from juvenile rather than adult chondrocytes.
NAV 1800
go.drugbank.com/drugs/DB05437ExperimentalRIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal
Navitoclax
go.drugbank.com/drugs/DB12340InvestigationalNavitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It is a substance being studied in the treatment of lymphomas and other types of cancer. … It blocks some of the enzymes that keep cancer cells from dying.
Synonyms: (R)-4-(3-Morpholin-4-Yl-1-Phenylsulfanylmethyl-Propylamino)-N-(4-{4-[2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-Enylmethyl]-Piperazin-1-Yl}-Benzoyl)-3-TrifluoromethanesulfonylbenzenesulfonamideNP-50301
go.drugbank.com/drugs/DB05662ExperimentalIt is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. … The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this
Ivarmacitinib
go.drugbank.com/drugs/DB16756InvestigationalIvarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. … While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis
Categories: Janus Kinase 1, antagonists & inhibitorsVicasinabin
go.drugbank.com/drugs/DB21587InvestigationalVicasinabin is under investigation in clinical trial NCT04265261 (A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic … Vicasinabin is a small molecule drug.
ADX-10061
go.drugbank.com/drugs/DB05419ExperimentalADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
Categories: Heterocyclic Compounds, 2-RingQR-333
go.drugbank.com/drugs/DB05533Investigationalthat can lead to numbness, skin ulcers, constant pain or extreme sensitivity to a stimulus. … QR-333 is a concentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder
EGT-301
go.drugbank.com/drugs/DB17649ExperimentalIt consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome … EGT-301 is a gene therapy being investigated for Hunter Syndrome.
Pateclizumab
go.drugbank.com/drugs/DB14997InvestigationalPateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared … With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis).